Bionano Genomics Inc (NASDAQ: BNGO) closed the day trading at $1.11 down -2.63% from the previous closing price of $1.14. In other words, the price has decreased by -$0.0300 from its previous closing price. On the day, 1593354 shares were traded.
Ratios:
For a better understanding of BNGO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.17 and its Current Ratio is at 1.40. In the meantime, Its Debt-to-Equity ratio is 0.91 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on January 05, 2023, initiated with a Sector Outperform rating and assigned the stock a target price of $4.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 13 ’23 when Mamuszka Hannah bought 65,789 shares for $0.76 per share. The transaction valued at 50,000 led to the insider holds 65,789 shares of the business.
Holmlin R. Erik bought 15,000 shares of BNGO for $9,639 on May 16 ’23. The President and CEO now owns 806,474 shares after completing the transaction at $0.64 per share. On May 12 ’23, another insider, Stewart Christopher P., who serves as the Chief Financial Officer of the company, bought 50,000 shares for $0.67 each. As a result, the insider paid 33,415 and bolstered with 281,373 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BNGO now has a Market Capitalization of 62.35M and an Enterprise Value of 39.88M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.68 while its Price-to-Book (P/B) ratio in mrq is 0.53. Its current Enterprise Value per Revenue stands at 1.10 whereas that against EBITDA is -0.19.
Stock Price History:
Over the past 52 weeks, BNGO has reached a high of $13.50, while it has fallen to a 52-week low of $1.04. The 50-Day Moving Average of the stock is 1.3434, while the 200-Day Moving Average is calculated to be 3.1595.
Shares Statistics:
Over the past 3-months, BNGO traded about 1.86M shares per day on average, while over the past 10 days, BNGO traded about 1.66M shares per day. A total of 54.69M shares are outstanding, with a floating share count of 53.87M. Insiders hold about 1.50% of the company’s shares, while institutions hold 11.30% stake in the company. Shares short for BNGO as of Feb 15, 2024 were 5.63M with a Short Ratio of 3.02, compared to 4.89M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 14.50% and a Short% of Float of 14.56%.
Earnings Estimates
Current recommendations for the stock of the company come from 4 analysts. On average, analysts expect EPS of -$0.87 for the current quarter, with a high estimate of -$0.75 and a low estimate of -$1.01, while EPS last year was -$1.3. The consensus estimate for the next quarter is -$0.63, with high estimates of -$0.57 and low estimates of -$0.68.
Analysts are recommending an EPS of between -$6.43 and -$6.8 for the fiscal current year, implying an average EPS of -$6.61. EPS for the following year is -$1.97, with 4 analysts recommending between -$1.51 and -$2.35.
Revenue Estimates
4 analysts predict $10.72M in revenue for the current quarter. It ranges from a high estimate of $11.11M to a low estimate of $10.1M. As of the current estimate, Bionano Genomics Inc’s year-ago sales were $8.21M, an estimated increase of 30.50% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $8.49M, an increase of 14.50% less than the figure of $30.50% in the same quarter last year. There is a high estimate of $8.65M for the next quarter, whereas the lowest estimate is $8.3M.
A total of 4 analysts have provided revenue estimates for BNGO’s current fiscal year. The highest revenue estimate was $36.5M, while the lowest revenue estimate was $35.5M, resulting in an average revenue estimate of $36.12M. In the same quarter a year ago, actual revenue was $27.8M, up 29.90% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $38.74M in the next fiscal year. The high estimate is $40.31M and the low estimate is $37.5M. The average revenue growth estimate for next year is up 7.30% from the average revenue estimate for this year.
